Logo image
The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe
Journal article   Open access   Peer reviewed

The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe

S.Y.C. Tong, J. Mora, A.C. Bowen, M.P. Cheng, N. Daneman, A.L. Goodman, G.S. Heriot, T.C. Lee, R.J. Lewis, D.C. Lye, …
Clinical Infectious Diseases, Vol.75(11), pp.2027-2034
2022
url
PublishedView
Published (Version of Record)CC BY V4.0 Open

Abstract

Staphylococcus aureus bloodstream (SAB) infection is a common and severe infectious disease, with a 90-day mortality of 15%–30%. Despite this, <3000 people have been randomized into clinical trials of treatments for SAB infection. The limited evidence base partly results from clinical trials for SAB infections being difficult to complete at scale using traditional clinical trial methods. Here we provide the rationale and framework for an adaptive platform trial applied to SAB infections. We detail the design features of the Staphylococcus aureus Network Adaptive Platform (SNAP) trial that will enable multiple questions to be answered as efficiently as possible. The SNAP trial commenced enrolling patients across multiple countries in 2022 with an estimated target sample size of 7000 participants. This approach may serve as an exemplar to increase efficiency of clinical trials for other infectious disease syndromes.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Industry collaboration
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.23 Antibiotics & Antimicrobials
1.23.173 MRSA and VRE
Web Of Science research areas
Immunology
Infectious Diseases
Microbiology
ESI research areas
Immunology
Logo image